Ensifentrine (RPL554): an inhaled ‘bifunctional’ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy. Clin. Immunol. 117(6), 1237–1243 (2006).
  Medline CASGoogle Scholar
• 2 Spina D, Page CP. Xanthines and phosphodiesterase inhibitors. Handb. Exp. Pharmacol. 237, 63–91 (2017).
  Medline CASGoogle Scholar
• 3 Schmidt DT, Watson N, Dent G et al. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br. J. Pharmacol. 131(8), 1607–1618 (2000).
  Medline CASGoogle Scholar
• 4 Billington CK, Le Jeune IR, Young KW, Hall IP. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 38(1), 1–7 (2008).
  Medline CASGoogle Scholar
• 5 Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin. Pharmacol. Toxicol. 114(5), 365–376 (2014).
  Medline CASGoogle Scholar
• 6 Beute J, Lukkes M, Koekoek EP et al. A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight 3(2), e94888 (2018).
  MedlineGoogle Scholar
• 7 Wright LC, Seybold J, Robichaud A, Adcock I, Barnes P. Phosphodiesterase expression in human epithelial cells. Am. J. Physiol. 275(4 Pt 1), L694–L700 (1998).
  Medline CASGoogle Scholar
• 8 Milara J, Navarro A, Almudever P, Lluch J, Morcillo EJ, Cortijo J. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/4 inhibition in human alveolar macrophages. Clin. Exp. Allergy 41(4), 535–546 (2011).
  Medline CASGoogle Scholar
• 9 Challiss RA, Adams D, Mistry R, Nicholson CD. Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle. Br. J. Pharmacol. 124(1), 47–54 (1998).
  Medline CASGoogle Scholar
• 10 Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br. J. Pharmacol. 157(6), 892–906 (2009).
  Medline CASGoogle Scholar
• 11 Page C, Cazzola M. Bifunctional drugs for the treatment of respiratory diseases. Handb. Exp. Pharmacol. 237, 197–212 (2017).
  Medline CASGoogle Scholar
• 12 Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol. Sci. 32(8), 495–506 (2011).
  Medline CASGoogle Scholar
• 13 Denis D, Riendeau D. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. Eur. J. Pharmacol. 367(2–3), 343–350 (1999).
  Medline CASGoogle Scholar
• 14 Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl -2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J. Pharmacol. Exp. Ther. 318(2), 840–848 (2006). • Fundamental article that illustrates the preclinical development of RPL554.
  Medline CASGoogle Scholar
• 15 Spina D, Ferlenga P, Biasini I et al. The effect duration of selective phosphodiesterase inhibitors in the guinea pig. Life Sci. 62(11), 953–965 (1998).
  Medline CASGoogle Scholar
• 16 Usinger P, Ruppe W. Pharmacodynamische effekte oraler Einzeldosen des vasodilators HL 725 an gesunden mannlichen Probanden. In: Miehlke K (Ed.). Verhandlungen der Deutschen Gesellschaft für innere Medizin: 90. Kongress. Springer, Berlin u.a (1984).
  Google Scholar
• 17 Liu S, Veilleux A, Young A et al. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 314(2), 846–854 (2005).
  Medline CASGoogle Scholar
• 18 Calzetta L, Page CP, Spina D et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J. Pharmacol. Exp. Ther. 346(3), 414–423 (2013). •• Demonstrates that RPL554 relaxes human bronchi and that it can interact with a muscarinic receptor antagonist to produce a synergistic inhibition of airway smooth muscle tone.
  Medline CASGoogle Scholar
• 19 Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm. Pharmacol. Ther. 32, 15–23 (2015). • RPL554 and glycopyrronium demonstrated a synergistic interaction in relaxing both human medium and small isolated bronchi, in terms of peak relaxation and an extended duration of action, suggesting that this combination may have a beneficial role in the treatment of asthma or chronic obstructive pulmonary disease (COPD).
  Medline CASGoogle Scholar
• 20 Venkatasamy R, Spina D. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br. J. Pharmacol. 173(15), 2335–2351 (2016).
  Medline CASGoogle Scholar
• 21 Keir S, Page CP. RPL554, a dual phosphodiesterase (PDE) 3/4 inhibitor acts synergistically with muscarinic receptor antagonists and beta-adrenoceptor agonists to produce bronchodilation in vivo. Am. J. Respir. Crit. Care Med. 189, A4218 (2014).
  Google Scholar
• 22 Turner MJ, Matthes E, Billet A et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. Lung Cell Mol. Physiol. 310(1), L59–L70 (2016).
  MedlineGoogle Scholar
• 23 Franciosi LG, Diamant Z, Banner KH et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir. Med. 1(9), 714–727 (2013). • A preliminary study documenting that inhaled RPL554 is an effective and well-tolerated bronchodilator, bronchoprotector and anti-inflammatory drug in asthma and COPD.
  Medline CASGoogle Scholar
• 24 Singh D, Abbott-Banner KH, Reid F, Newman K. A Phase I, randomised, double blind, placebo controlled, study to assess the safety, tolerability and pharmacokinetics of multiple inhaled doses of RPL554 administered by nebuliser to healthy male subjects and stable COPD patients. Am. J. Respir. Crit. Care Med. 193, A6838 (2016). • An interesting study that documents the value of using RPL554 as an add-on drug in the treatment of COPD.
  Google Scholar
• 25 Bjermer L, Stewart J, Abbott-Banner K, Newman K. RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects. Eur. Respir. J. 48, PA4905 (2016).
  Google Scholar
• 26 McNee S. Verona's RPL554 improves lung function in CF trial (2018). www.pharmatimes.com/news/veronas_rpl554_improves_lung_function_in_cf_trial_1225272.
  Google Scholar
• 27 Newman KB, Armstrong M, Maurer BT, Ayrton J, Causon R. Low oral bioavailability of RPL554, a first-in-class dual PDE3/4 inhibitor, demonstrates that its nebulized, inhaled formulation is appropriate for delivering optimal pulmonary dose. Am. J. Respir. Crit. Care Med. 197, A3022 (2018).
  Google Scholar
• 28 Singh D, Abbott-Banner K, Newman K. RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients. Eur. Respir. J. 48, PA4052 (2016).
  Google Scholar
• 29 Singh D, Abbott-Banner K, Newman K. The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients. Eur. Respir. J. 48, OA1970 (2016).
  Google Scholar
• 30 Newman KB, Singh D. RPL554, a first-in-class dual PDE3/4 inhibitor, causes rapid additional bronchodilation when dosed with tiotropium in COPD patients. Am. J. Respir. Crit. Care Med. 197, A4227 (2018).
  Google Scholar
• 31 Melao A. Verona's RPL554 seems to improve COPD lung function, trial results show (2018). https://copdnewstoday.com/2018/04/03/verona-rpl554-improves-copd-lung-function-phase-2-trial/.
  Google Scholar
• 32 Anonymous. Verona Pharma begins Phase ll trial of RPL554 for COPD (2018). www.drugdevelopment-technology.com/news/verona-pharma-begins-phase-ll-trial-rpl554-copd/.
  Google Scholar
• 33 Grootendorst DC, Gauw SA, Verhoosel RM et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62(12), 1081–1087 (2007).
  MedlineGoogle Scholar
• 34 Bardin P, Kanniess F, Gauvreau G, Bredenbröker D, Rabe KF. Roflumilast for asthma: efficacy findings in mechanism of action studies. Pulm. Pharmacol. Ther. 35(Suppl.), S4–S10 (2015).
  Medline CASGoogle Scholar
• 35 Arievich H, Overend T, Renard D et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm. Med. 12, 74 (2012).
  Medline CASGoogle Scholar
• 36 Matera MG, Cazzola M. Muscarinic receptor antagonists. Handb. Exp. Pharmacol. 237, 41–62 (2017).
  Medline CASGoogle Scholar
• 37 van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJ. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 19(4), 639–644 (2002).
  Medline CASGoogle Scholar
• 38 Yick CY, Zwinderman AH, Kunst PW et al. Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls. Eur. Respir. J. 42(3), 662–670 (2013).
  Medline CASGoogle Scholar